Business Description
Immunome Inc
NAICS : 541714
SIC : 2833
ISIN : US45257U1088
Share Class Description:
IMNM: Ordinary SharesDescription
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 190.59 | |||||
| Equity-to-Asset | 0.89 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.04 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 12.65 | |||||
| Beneish M-Score | -0.36 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 34.5 | |||||
| 3-Year EPS without NRI Growth Rate | 28.8 | |||||
| 3-Year FCF Growth Rate | 51.7 | |||||
| 3-Year Book Growth Rate | -10.7 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 34.74 | |||||
| 9-Day RSI | 35.91 | |||||
| 14-Day RSI | 35.01 | |||||
| 6-1 Month Momentum % | 137.11 | |||||
| 12-1 Month Momentum % | 203.05 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 10.18 | |||||
| Quick Ratio | 10.18 | |||||
| Cash Ratio | 10.07 | |||||
| Days Sales Outstanding | 18 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -59.6 | |||||
| Shareholder Yield % | -26.07 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -351.67 | |||||
| Net Margin % | -1829.44 | |||||
| FCF Margin % | -479.44 | |||||
| ROE % | -266.86 | |||||
| ROA % | -178.21 | |||||
| ROIC % | -214.71 | |||||
| ROC (Joel Greenblatt) % | -1659.67 | |||||
| ROCE % | -42.55 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 17.76 | |||||
| PB Ratio | 3.08 | |||||
| Price-to-Tangible-Book | 3.1 | |||||
| Price-to-Free-Cash-Flow | 40.66 | |||||
| EV-to-EBIT | -25.82 | |||||
| EV-to-EBITDA | -26.5 | |||||
| EV-to-Revenue | 52.92 | |||||
| EV-to-FCF | -12.2 | |||||
| Price-to-Net-Current-Asset-Value | 3.16 | |||||
| Price-to-Net-Cash | 3.2 | |||||
| Earnings Yield (Greenblatt) % | -3.87 | |||||
| FCF Yield % | -0.95 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:IMNM
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Immunome Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 12.683 | ||
| EPS (TTM) ($) | -15.512 | ||
| Beta | 2.25 | ||
| Volatility % | 107.72 | ||
| 14-Day RSI | 35.01 | ||
| 14-Day ATR ($) | 1.076906 | ||
| 20-Day SMA ($) | 15.0375 | ||
| 12-1 Month Momentum % | 203.05 | ||
| 52-Week Range ($) | 4.5 - 30.958 | ||
| Shares Outstanding (Mil) | 59.94 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Immunome Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Immunome Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Immunome Inc Frequently Asked Questions
What is Immunome Inc(IMNM)'s stock price today?
The current price of IMNM is $14.80. The 52 week high of IMNM is $30.96 and 52 week low is $4.50.
When is next earnings date of Immunome Inc(IMNM)?
The next earnings date of Immunome Inc(IMNM) is 2024-08-09 Est..
Does Immunome Inc(IMNM) pay dividends? If so, how much?
Immunome Inc(IMNM) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers